Carew v. Lifecore Biomedical, Inc.

U.S. District Court, District of Minnesota

Carew v. Lifecore Biomedical, Inc.

Trial Court Opinion

             UNITED STATES DISTRICT COURT                             
                DISTRICT OF MINNESOTA                                 


DAVID  CAREW,  Individually  and  on  Case No. 24-cv-3028 (LMP/JFD)       
Behalf of All Others Similarly Situated,                                  

                Plaintiff,                                            

v.                                   ORDER GRANTING LEAD                  
                                    PLAINTIFF STATUS                  
LIFECORE BIOMEDICAL, INC.,                                                
ALBERT D. BOLLES, JAMES G.                                                
HALL, BRIAN MCLAUGHLIN,                                                   
and JOHN MORBERG,                                                         

                Defendants.                                           


Robert K. Shelquist, Gregg M. Fishbein, Rebecca A. Peterson, Lockridge Grindal 
Nauen PLLP, Minneapolis, MN; Jeremy A. Lieberman, J. Alexander Hood II,   
Pomerantz LLP, New York, NY, for Plaintiff David Carew.                   
Carl V. Malmstrom, Wolf Haldenstein Adler Freeman & Herz LLC, Chicago, IL; 
Phillip Kim, Laurence M. Rosen, The Rosen Law Firm, P.A., New York, NY; Brian 
Schall, The Schall Law Firm, Los Angeles, CA, for Plaintiff Hugh Robert Holmes. 
Andrew R. Gray, Latham & Watkins LLP, Costa Mesa, CA; James K. Langdon,   
Michael E. Rowe, Dorsey & Whitney LLP, Minneapolis, MN, for Defendants.   

 On July 29, 2024, Plaintiff David Carew filed a putative securities class action on 
behalf of himself and all others similarly situated, against Lifecore Biomedical, Inc., Albert 
D. Bolles, James G. Hall, Brian McLaughlin, and John Morberg (collectively “Lifecore”).  
ECF No. 1.  On September 27, 2024, Carew and another individual plaintiff, Hugh Robert 
Holmes, filed motions seeking to have the Court appoint them as lead plaintiff and appoint 
their chosen counsel as lead counsel.  ECF Nos. 17, 23.  On October 4, 2024, Carew and 
Holmes (collectively “Movants”) filed a joint stipulation, asking the Court to appoint them 
both as co-lead plaintiffs and to appoint Pomerantz LLP and the Rosen Law Firm as co-

lead counsel, and Lockridge Grindal Nauen PLLP as 1iaison counsel.  ECF No. 28. 
 Under the PSLRA, the Court is required to “appoint as lead plaintiff the member or 
members of the purported plaintiff class that the court determines to be most capable of 
adequately representing the interests of class members.” 15 U.S.C. § 78u-4(a)(3)(B)(i).  
When multiple plaintiffs move to be appointed lead plaintiff, the Court must adopt a 
presumption  that the  “most  adequate  plaintiff”  is  the  plaintiff  who  has:  (1) filed  the 

complaint or moved for appointment as lead plaintiff; (2) has the largest financial interest 
in the relief sought by the class; and (3) otherwise satisfies the requirements of Rule 23 of 
the Federal Rules of Civil Procedure.  Id. § 78u-4(a)(3)(B)(iii)(I).  Once established, the 
presumption of the “most adequate plaintiff” can be rebutted only “upon proof by a member 
of the purported plaintiff class that” the lead plaintiff “will not fairly and adequately protect 

the interests of the class; or . . . is subject to unique defenses that render such plaintiff 
incapable  of  adequately  representing  the  class.”    Id.  §  78u-4(a)(3)(B)(iii)(II).    Once 
established, the most adequate plaintiff “select[s] and retain[s] counsel to represent the 
class,” pursuant to court approval.  Id. § 78u-4(a)(3)(B)(v).             
 Here, there is no objection to either Carew’s or Holmes’s qualifications to represent 

the class as lead plaintiff.  And the Court finds no reason to disagree.  First, Carew and 
Holmes both “moved for appointment as lead plaintiff.  Second, they both assert significant 
financial loss.  Indeed, Carew asserts he lost $185,349, ECF No. 19 at 19, and Holmes 
asserts he lost $311,139, ECF No. 24 at 11. Third, they both assert that they have typical 
claims representative of any other class member in that they claim Lifecore violated 
securities law by making false and misleading statements and inflating their share price as 

a result.  Fourth, they both pledge to adequately and vigorously represent the class as a 
whole.  ECF No. 19 at 21–23; ECF No. 24 at 12–13.  Moreover, both have selected counsel 
with extensive experience litigating securities class actions on behalf of plaintiffs, in this 
District and elsewhere.  See, e.g., Steamfitters Loc. 449 Pension & Ret. Sec. Funds v. Sleep 
No. Corp., No. 21-CV-2669 (PJS/BRT), 
2022 WL 1607306
, at *7 (D. Minn. May 20, 2022) 
(appointing Pomerantz as lead counsel); Gru v. Axsome Therapeutics, Inc., No. 22-CV-

3925 (LGS), 
2024 WL 230744
, at *2 (S.D.N.Y. Jan. 22, 2024) (“This Court has previously 
determined that both firms are capable of serving as lead counsel.”); Tchatchou v. India 
Globalization Cap., Inc., No. 8:18-CV-03396 (PWG), 
2019 WL 1004591
, at *9 (D. Md. 
Feb. 28, 2019) (“There is no dispute that these firms have considerable experience with 
securities class actions such as this one.”).  In short, the Court does not doubt that both 

individual plaintiffs and their respective law firms can adequately represent the class as a 
whole.                                                                    
 Indeed, instead of competing for status as the lead plaintiff, Movants ask the Court 
to appoint them as co-lead plaintiffs, asserting that “it is in the putative class’s best interest” 
and pointing out that their respective chosen counsel have worked together “efficiently and 

successfully” as co-lead counsel in previous cases.  ECF No. 28 at 2–3.   
 Despite the parties’ unobjected-to stipulation, the Court has an independent duty to 
assess whether a co-lead plaintiff structure is appropriate here, as the decision to appoint 
co-lead plaintiffs is “within the discretion of the [district] [c]ourt.”  Miller v. Ventro Corp., 
No. 01-CV-1287 (VKA), 
2001 WL 34497752
, at *9 (N.D. Cal. Nov. 28, 2001).  When 
considering the question, “[f]ederal courts have reached varying conclusions concerning 

the propriety of appointing co-lead plaintiffs,” Pirelli Armstrong Tire Corp. Retiree Med. 
Benefits Tr. v. LaBranche & Co., 
229 F.R.D. 395, 418
 (S.D.N.Y. 2004).  And while there is 
no “arbitrary limit on the number of proposed lead plaintiffs the Court may appoint,” courts 
nevertheless consider the question on a “case-by-case” inquiry.  Steamfitters, 
2022 WL 1607306
, at *6 (internal quotations and citations omitted).               
 Here, the Court is persuaded that the appointment of co-lead plaintiffs is appropriate.  

Movants are both individual investors, and “[c]o-lead plaintiffs are particularly appropriate 
in a case such as this, in which it appears that there are two or more smaller investors with 
roughly equal interests.”  
Id.
 (internal quotations omitted).  Indeed, the Court “does have 
an  interest  in  managing  and  maintaining  the  orderly  progression  of  the  case,”  and 
appointing co-lead plaintiffs when both are individual investors would protect against “any 

interruption in the litigation” that might arise should one or the other prove susceptible to 
individual defenses.  Lusk v. Life Time Fitness, Inc., No. 15-CV-1911 (JRT/JJK), 
2015 WL 9858177
, at *2 (D. Minn. July 10, 2015); Pirelli, 
229 F.R.D. at 420
 (noting that “a co-lead 
structure here will have the salutary effect of providing greater stability in the prosecution 
of these consolidation actions, should a decision be reached at some later stage in the 

litigation that either co-lead plaintiff will not adequately represent the class”).  And a co-
lead plaintiff structure “will help to ensure that adequate resources and experience are 
available.”  Steamfitters, 
2022 WL 1607306
, at *6.                        
 Having approved a co-lead plaintiff structure here, the Court must next consider the 
Movants’ proposed co-lead counsel structure.  15 U.S.C. § 78u-4(a)(3)(B)(v); see also 

Lusk, 
2015 WL 9858177
, at *2 (“In light of this Court’s determination that appointment of 
co-lead plaintiffs would be appropriate, it follows that appointment of co-lead counsel and 
co-liaison counsel is warranted.”).  Movants here agree that Pomerantz LLP and the Rosen 
Law Firm should serve as co-lead counsel, and Lockridge Grindal Nauen PLLP as local 
liaison counsel.  ECF No. 28.  The Court is sufficiently persuaded that the chosen counsel 
is appropriate.  Not only do Pomerantz LLP and the Rosen Law Firm have extensive 

experience litigating securities class actions, but experience doing so together.  See Gru, 
2024 WL 230744
,  at  *2  (approving  “Pomerantz  and  Rosen  Law”  as  co-counsel); 
Tchatchou, 
2019 WL 1004591
, at *9 (same).  Thus, proposed co-lead counsel should be 
capable of efficiently and effectively managing this litigation.          
 Nevertheless,  the  Court  is  ultimately  responsible  for  protecting  the  financial 

interests of the class, and for approving “[t]otal attorneys’ fees and expenses.”  15 U.S.C.A. 
§ 78u-4.  Accordingly, the Court instructs co-lead counsel that they are to work together to 
ensure that efforts are not duplicated, and that “the use of co-lead counsel does not in any 
way increase attorney’s fees.”  Steamfitters, 
2022 WL 1607306
, at *7.  While the Court is 
persuaded that co-lead counsel “will be able to efficiently prosecute this litigation with 

minimal overlap or duplication of effort and expense,” co-lead counsel are reminded that 
the Court will be reviewing carefully the work of counsel and scrutinizing attorneys’ fees 
and expenses submissions “to make sure that there is no unnecessary duplication of work 
and that efficiency is maximized in the allocation of work among the law firms.”  Lusk, 
2015 WL 9858177
, at *2.                                                   

ORDER

 Based on the foregoing, and all the files, records, and proceedings herein, IT IS 
HEREBY ORDERED that:                                                      
1.  Carew’s Motion to Appoint Counsel and to Appoint David Carew as Lead Plaintiff 
  (ECF No. 17) is GRANTED in part;                                    
2.  Holmes’s Motion to Appoint Lead Plaintiff and Approve Lead Plaintiff’s Selection 
  of Counsel (ECF No. 23) is GRANTED in part;                         

3.  Carew and Holmes are appointed as co-lead plaintiffs; and         
4.  Pomerantz LLP and the Rosen Law Firm are approved as co-lead counsel with 
  Lockridge Grindal Nauen PLLP approved as local liaison counsel, provided this 
  case is efficiently prosecuted without overlap or duplication of effort and expense. 
5.  Pursuant to the Court’s prior order (ECF No. 13), the parties must confer within 

  ten business days on a schedule to file a consolidated or amended complaint and 
  for Defendants to respond.  The parties must file the schedule with the Court 
  within thirty business days.                                        

Dated: November 15, 2024                          s/Laura M. Provinzino   
                               Laura M. Provinzino                    
                               United States District Judge           

Trial Court Opinion

             UNITED STATES DISTRICT COURT                             
                DISTRICT OF MINNESOTA                                 


DAVID  CAREW,  Individually  and  on  Case No. 24-cv-3028 (LMP/JFD)       
Behalf of All Others Similarly Situated,                                  

                Plaintiff,                                            

v.                                   ORDER GRANTING LEAD                  
                                    PLAINTIFF STATUS                  
LIFECORE BIOMEDICAL, INC.,                                                
ALBERT D. BOLLES, JAMES G.                                                
HALL, BRIAN MCLAUGHLIN,                                                   
and JOHN MORBERG,                                                         

                Defendants.                                           


Robert K. Shelquist, Gregg M. Fishbein, Rebecca A. Peterson, Lockridge Grindal 
Nauen PLLP, Minneapolis, MN; Jeremy A. Lieberman, J. Alexander Hood II,   
Pomerantz LLP, New York, NY, for Plaintiff David Carew.                   
Carl V. Malmstrom, Wolf Haldenstein Adler Freeman & Herz LLC, Chicago, IL; 
Phillip Kim, Laurence M. Rosen, The Rosen Law Firm, P.A., New York, NY; Brian 
Schall, The Schall Law Firm, Los Angeles, CA, for Plaintiff Hugh Robert Holmes. 
Andrew R. Gray, Latham & Watkins LLP, Costa Mesa, CA; James K. Langdon,   
Michael E. Rowe, Dorsey & Whitney LLP, Minneapolis, MN, for Defendants.   

 On July 29, 2024, Plaintiff David Carew filed a putative securities class action on 
behalf of himself and all others similarly situated, against Lifecore Biomedical, Inc., Albert 
D. Bolles, James G. Hall, Brian McLaughlin, and John Morberg (collectively “Lifecore”).  
ECF No. 1.  On September 27, 2024, Carew and another individual plaintiff, Hugh Robert 
Holmes, filed motions seeking to have the Court appoint them as lead plaintiff and appoint 
their chosen counsel as lead counsel.  ECF Nos. 17, 23.  On October 4, 2024, Carew and 
Holmes (collectively “Movants”) filed a joint stipulation, asking the Court to appoint them 
both as co-lead plaintiffs and to appoint Pomerantz LLP and the Rosen Law Firm as co-

lead counsel, and Lockridge Grindal Nauen PLLP as 1iaison counsel.  ECF No. 28. 
 Under the PSLRA, the Court is required to “appoint as lead plaintiff the member or 
members of the purported plaintiff class that the court determines to be most capable of 
adequately representing the interests of class members.” 15 U.S.C. § 78u-4(a)(3)(B)(i).  
When multiple plaintiffs move to be appointed lead plaintiff, the Court must adopt a 
presumption  that the  “most  adequate  plaintiff”  is  the  plaintiff  who  has:  (1) filed  the 

complaint or moved for appointment as lead plaintiff; (2) has the largest financial interest 
in the relief sought by the class; and (3) otherwise satisfies the requirements of Rule 23 of 
the Federal Rules of Civil Procedure.  Id. § 78u-4(a)(3)(B)(iii)(I).  Once established, the 
presumption of the “most adequate plaintiff” can be rebutted only “upon proof by a member 
of the purported plaintiff class that” the lead plaintiff “will not fairly and adequately protect 

the interests of the class; or . . . is subject to unique defenses that render such plaintiff 
incapable  of  adequately  representing  the  class.”    Id.  §  78u-4(a)(3)(B)(iii)(II).    Once 
established, the most adequate plaintiff “select[s] and retain[s] counsel to represent the 
class,” pursuant to court approval.  Id. § 78u-4(a)(3)(B)(v).             
 Here, there is no objection to either Carew’s or Holmes’s qualifications to represent 

the class as lead plaintiff.  And the Court finds no reason to disagree.  First, Carew and 
Holmes both “moved for appointment as lead plaintiff.  Second, they both assert significant 
financial loss.  Indeed, Carew asserts he lost $185,349, ECF No. 19 at 19, and Holmes 
asserts he lost $311,139, ECF No. 24 at 11. Third, they both assert that they have typical 
claims representative of any other class member in that they claim Lifecore violated 
securities law by making false and misleading statements and inflating their share price as 

a result.  Fourth, they both pledge to adequately and vigorously represent the class as a 
whole.  ECF No. 19 at 21–23; ECF No. 24 at 12–13.  Moreover, both have selected counsel 
with extensive experience litigating securities class actions on behalf of plaintiffs, in this 
District and elsewhere.  See, e.g., Steamfitters Loc. 449 Pension & Ret. Sec. Funds v. Sleep 
No. Corp., No. 21-CV-2669 (PJS/BRT), 
2022 WL 1607306
, at *7 (D. Minn. May 20, 2022) 
(appointing Pomerantz as lead counsel); Gru v. Axsome Therapeutics, Inc., No. 22-CV-

3925 (LGS), 
2024 WL 230744
, at *2 (S.D.N.Y. Jan. 22, 2024) (“This Court has previously 
determined that both firms are capable of serving as lead counsel.”); Tchatchou v. India 
Globalization Cap., Inc., No. 8:18-CV-03396 (PWG), 
2019 WL 1004591
, at *9 (D. Md. 
Feb. 28, 2019) (“There is no dispute that these firms have considerable experience with 
securities class actions such as this one.”).  In short, the Court does not doubt that both 

individual plaintiffs and their respective law firms can adequately represent the class as a 
whole.                                                                    
 Indeed, instead of competing for status as the lead plaintiff, Movants ask the Court 
to appoint them as co-lead plaintiffs, asserting that “it is in the putative class’s best interest” 
and pointing out that their respective chosen counsel have worked together “efficiently and 

successfully” as co-lead counsel in previous cases.  ECF No. 28 at 2–3.   
 Despite the parties’ unobjected-to stipulation, the Court has an independent duty to 
assess whether a co-lead plaintiff structure is appropriate here, as the decision to appoint 
co-lead plaintiffs is “within the discretion of the [district] [c]ourt.”  Miller v. Ventro Corp., 
No. 01-CV-1287 (VKA), 
2001 WL 34497752
, at *9 (N.D. Cal. Nov. 28, 2001).  When 
considering the question, “[f]ederal courts have reached varying conclusions concerning 

the propriety of appointing co-lead plaintiffs,” Pirelli Armstrong Tire Corp. Retiree Med. 
Benefits Tr. v. LaBranche & Co., 
229 F.R.D. 395, 418
 (S.D.N.Y. 2004).  And while there is 
no “arbitrary limit on the number of proposed lead plaintiffs the Court may appoint,” courts 
nevertheless consider the question on a “case-by-case” inquiry.  Steamfitters, 
2022 WL 1607306
, at *6 (internal quotations and citations omitted).               
 Here, the Court is persuaded that the appointment of co-lead plaintiffs is appropriate.  

Movants are both individual investors, and “[c]o-lead plaintiffs are particularly appropriate 
in a case such as this, in which it appears that there are two or more smaller investors with 
roughly equal interests.”  
Id.
 (internal quotations omitted).  Indeed, the Court “does have 
an  interest  in  managing  and  maintaining  the  orderly  progression  of  the  case,”  and 
appointing co-lead plaintiffs when both are individual investors would protect against “any 

interruption in the litigation” that might arise should one or the other prove susceptible to 
individual defenses.  Lusk v. Life Time Fitness, Inc., No. 15-CV-1911 (JRT/JJK), 
2015 WL 9858177
, at *2 (D. Minn. July 10, 2015); Pirelli, 
229 F.R.D. at 420
 (noting that “a co-lead 
structure here will have the salutary effect of providing greater stability in the prosecution 
of these consolidation actions, should a decision be reached at some later stage in the 

litigation that either co-lead plaintiff will not adequately represent the class”).  And a co-
lead plaintiff structure “will help to ensure that adequate resources and experience are 
available.”  Steamfitters, 
2022 WL 1607306
, at *6.                        
 Having approved a co-lead plaintiff structure here, the Court must next consider the 
Movants’ proposed co-lead counsel structure.  15 U.S.C. § 78u-4(a)(3)(B)(v); see also 

Lusk, 
2015 WL 9858177
, at *2 (“In light of this Court’s determination that appointment of 
co-lead plaintiffs would be appropriate, it follows that appointment of co-lead counsel and 
co-liaison counsel is warranted.”).  Movants here agree that Pomerantz LLP and the Rosen 
Law Firm should serve as co-lead counsel, and Lockridge Grindal Nauen PLLP as local 
liaison counsel.  ECF No. 28.  The Court is sufficiently persuaded that the chosen counsel 
is appropriate.  Not only do Pomerantz LLP and the Rosen Law Firm have extensive 

experience litigating securities class actions, but experience doing so together.  See Gru, 
2024 WL 230744
,  at  *2  (approving  “Pomerantz  and  Rosen  Law”  as  co-counsel); 
Tchatchou, 
2019 WL 1004591
, at *9 (same).  Thus, proposed co-lead counsel should be 
capable of efficiently and effectively managing this litigation.          
 Nevertheless,  the  Court  is  ultimately  responsible  for  protecting  the  financial 

interests of the class, and for approving “[t]otal attorneys’ fees and expenses.”  15 U.S.C.A. 
§ 78u-4.  Accordingly, the Court instructs co-lead counsel that they are to work together to 
ensure that efforts are not duplicated, and that “the use of co-lead counsel does not in any 
way increase attorney’s fees.”  Steamfitters, 
2022 WL 1607306
, at *7.  While the Court is 
persuaded that co-lead counsel “will be able to efficiently prosecute this litigation with 

minimal overlap or duplication of effort and expense,” co-lead counsel are reminded that 
the Court will be reviewing carefully the work of counsel and scrutinizing attorneys’ fees 
and expenses submissions “to make sure that there is no unnecessary duplication of work 
and that efficiency is maximized in the allocation of work among the law firms.”  Lusk, 
2015 WL 9858177
, at *2.                                                   

ORDER

 Based on the foregoing, and all the files, records, and proceedings herein, IT IS 
HEREBY ORDERED that:                                                      
1.  Carew’s Motion to Appoint Counsel and to Appoint David Carew as Lead Plaintiff 
  (ECF No. 17) is GRANTED in part;                                    
2.  Holmes’s Motion to Appoint Lead Plaintiff and Approve Lead Plaintiff’s Selection 
  of Counsel (ECF No. 23) is GRANTED in part;                         

3.  Carew and Holmes are appointed as co-lead plaintiffs; and         
4.  Pomerantz LLP and the Rosen Law Firm are approved as co-lead counsel with 
  Lockridge Grindal Nauen PLLP approved as local liaison counsel, provided this 
  case is efficiently prosecuted without overlap or duplication of effort and expense. 
5.  Pursuant to the Court’s prior order (ECF No. 13), the parties must confer within 

  ten business days on a schedule to file a consolidated or amended complaint and 
  for Defendants to respond.  The parties must file the schedule with the Court 
  within thirty business days.                                        

Dated: November 15, 2024                          s/Laura M. Provinzino   
                               Laura M. Provinzino                    
                               United States District Judge           

Reference

Status
Unknown